# miR Sentinel

Source: https://onco.cc/drugs/mir-sentinel/  
OnCo record `mir-sentinel` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A urine test that reads small RNAs from tiny vesicles to detect prostate cancer and judge its grade, so far validated in a case-control study.

## Summary

MiRNA Scientific calls it "the first and only non-invasive liquid biopsy urine test that accurately detects, classifies and can monitor prostate cancer at the molecular level" (the maker's claim). Its first report interrogated small non-coding RNAs from urinary vesicles of 235 participants on microarrays and was then validated in a case-control sample of 1,436 subjects with 94 per cent sensitivity and 92 per cent specificity (Wang 2020). No regulatory or coverage status was found.

## Fields

- Kind: Test
- Status: emerging
- Last checked: 2026-11-04
- Also known as: Sentinel PCa Test; miR Sentinel prostate test
- Tags: test; rna
- Brand: miR Sentinel
- Modality: Urine extracellular vesicle small non-coding RNA test (prostate cancer)
- Mechanism: Small non-coding RNAs from urinary vesicles are read on microarrays and classified to separate prostate cancer from no cancer and low from higher grade.

## Sources

- MiRNA Scientific: https://mirnascientific.com

## Connected records

- drugs: [ExoDx Prostate (IntelliScore)](https://onco.cc/drugs/exodx-prostate/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Liquid RNA biopsy (cell-free, vesicle and platelet RNA)](https://onco.cc/technologies/liquid-rna-biopsy/)
- key papers: [Expression of Small Noncoding RNAs in Urinary Exosomes Classifies Prostate Cancer into Indolent and Aggressive Disease](https://onco.cc/key-papers/paper-wang-urinary-exosome-small-rna-prostate-j-urol-2020/)

---
JSON: https://onco.cc/api/v1/entities/mir-sentinel.json